Glenmark bets on respiratory drug, licensing deals to improve business

Glenmark Pharmaceuticals is banking on global rollout of specialty respiratory drug Ryaltris, making its US-based innovation unit Ichnos self-sustaining through more licensing deals, and expansion of branded formulation business in India, to help...

How New operating models are impacting pharma sector

Like many other industries in the pharmaceutical industry the pandemic suddenly made enterprises to operate differently. For example, all the in-person meetings became virtual.

Indian pharma industry likely to grow $130 bn by 2030

The Indian pharma industry is expected to grow to $130 billion by 2030 and become the leading provider of medicines to the world, said Indian Pharmaceutical Alliance (IPA) Secretary General...

Singapore grants interim approval for Moderna's bivalent COVID-19 booster vaccine

Singapore granted interim authorisation for a bivalent COVID-19 booster vaccine made by Moderna, the government said in a statement...

Pfizer starts late-stage trial of mRNA-based flu vaccine

Pfizer Inc said it had started a late-stage U.S. trial of an influenza vaccine involving 25,000 patients, among the first such studies for a messenger RNA flu shot...

Diabetes, patented TB, HIV drugs enter essential list

Prices of several anti-diabetes drugs, patented antivirals used in the treatment of tuberculosis, HIV and hepatitis C are set to get cheaper with their inclusion in the latest edition of National List of Essential Medicines, 2022...

Lupin gets approval for arthritis drug from Canadian health authority

Drug maker Lupin said its biosimilar product Rymti, indicated for the treatment of arthritis, has received approval from the Canadian health authority. The firm's product is the biosimilar of the reference drug Enbrel...

Piramal Pharma in talks for $225 million offshore loans

Piramal Pharma, the recently spun-off unit of Piramal Enterprises, is set to raise $225 million in offshore loans as the drugmaker looks to improve its financial metrics ahead of its impending listing as an independent company, people familiar with..

Drug regulator's approves phase-3 study of intranasal Covid vaccine in 5-18 age group

Hyderabad-based firm Bharat Biotech has sought permission from the drug regulator to conduct phase-3 study of its intranasal COVID-19 vaccine in the 5 to 18 age group. On September 6, the Drugs Controller General of India (DCGI) had approved...

How will wearable technology impact the pharmaceutical industry

Wearable technology in healthcare is growing rapidly with several advanced features which are expected to offer significant advantages for pharma enterprises

on the deck


Most Viewed

Editor's Guest


© 2025 India Pharma Outlook. All Rights Reserved.